Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival
2003

Bisphosphonates and Breast Cancer Cell Survival

publication Evidence: moderate

Author Information

Author(s): Fromigue O, Kheddoumi N, Body J-J

Primary Institution: Institut Jules Bordet, Université Libre de Bruxelles

Hypothesis

Can bisphosphonates inhibit the protective effects of bone-derived growth factors on breast cancer cell survival?

Conclusion

Bisphosphonates can reduce the stimulatory effects of growth factors on breast cancer cell survival.

Supporting Evidence

  • Bisphosphonates reduced the skeletal morbidity rate in breast cancer patients with bone metastases by up to 40-50%.
  • Bisphosphonates can induce human breast cancer cell death in vitro.
  • Growth factors like IGF-I and FGF-2 promote breast cancer cell survival.

Takeaway

This study shows that certain drugs called bisphosphonates can help fight breast cancer by stopping the cancer cells from using helpful substances in the bone that help them grow.

Methodology

The study used MTT tests to assess cell viability and caspase activity to evaluate apoptosis in breast cancer cell lines treated with bisphosphonates and growth factors.

Limitations

The exact concentrations of bisphosphonates in vivo are difficult to determine, and the study primarily focused on in vitro conditions.

Statistical Information

P-Value

p<0.005

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6601009

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication